NeuroMyst Pro
Multi-waveform (tDCS + tACS + tRNS) at sub-$250 — closest thing to Foc.us V3 feature set at half the price
NOT CLEARED
No FDA clearance, registration, or CE marking found.
Key facts at a glance.
- Founded
- 2021
- Headquarters
- USA
- Price range
- $159.99–$224.99
The real price over three years.
Total cost of ownership · 3yr
| Hardwareone-time | $159.99 |
| 3-year total | $159.99 |
What the device does.
- + Combines tDCS, tACS, and tRNS in single device
- + Verified accurate current delivery per third-party testing
- + Auto ramp up/down and session timer
- + Pro and Pro Plus variants
- + Portable, battery-powered
- + Adjustable intensity
The trade-offs.
- + **Multi-waveform (tDCS + tACS + tRNS)** at sub-$250 pricing
- + **Closest thing to Foc.us V3 feature set at half the price**
- + $159.99-224.99 mid-tier accessible pricing
- + 2021-founded USA with rapid execution
- + Power-user features at consumer price point
- − Not FDA-cleared
- − 2021-founded with limited longitudinal track record
- − Smaller brand awareness vs Foc.us V3 / Caputron
- − Multi-waveform complexity adds learning curve
- − Limited consumer-experience signal documentation
Biohackers wanting multi-modality stimulation (tDCS/tACS/tRNS) at consumer price
The long read.
§ Hands-on instrument testing pending. Based on published specifications and third-party data.
Overview
NeuroMyst Pro is the multi-waveform tDCS + tACS + tRNS sub-$250 specialist — founded 2021 in USA, with structural value claim built on multi-waveform (tDCS + tACS + tRNS) capability at sub-$250 — closest thing to Foc.us V3 feature set at half the price at $159.99-224.99. For power-users wanting Foc.us V3-equivalent waveform flexibility at meaningfully lower price, NeuroMyst Pro is structurally distinctive.
The structural editorial caveats: not FDA-cleared, 2021-founded with limited longitudinal track record, smaller brand awareness vs Foc.us V3 / Caputron, multi-waveform complexity adds learning curve, and limited consumer-experience signal.
When NeuroMyst Pro Makes Sense
Strong fit: Foc.us V3-equivalent multi-waveform priority at half price; tDCS + tACS + tRNS combo preference; cost-priority within power-user tier; new-brand willingness to absorb track-record risk.
Weaker fit: Established multi-year DIY positioning (Foc.us V3 since 2012); FDA-cleared positioning (Caputron, Flow Neuroscience); idiot-proof entry (TheBrainDriver V2.1); EU prescribed (Sooma).
3-Year Cost of Ownership
| Use case | Cost |
|---|---|
| NeuroMyst Pro | ~$159.99-224.99 |
Compare: Foc.us V3 ($188-399 multi-year established), Caputron ActivaDose ($249-449 off-label cleared), TheBrainDriver V2.1 ($127-150), Brain Premier ($99-175).
Verdict: Recommended
NeuroMyst Pro earns a recommended verdict on multi-waveform (tDCS + tACS + tRNS) sub-$250 positioning, closest-Foc.us-V3-equivalent at half the price, $159.99-224.99 mid-tier accessible pricing, and 2021-founded rapid execution — balanced against not-FDA-cleared, 2021-founded limited track record, smaller brand awareness, multi-waveform complexity, and limited consumer-experience signal.
For Foc.us V3-equivalent multi-waveform priority at half price, structurally distinctive. For established multi-year DIY (Foc.us V3), FDA clearances, or idiot-proof entry, alternatives are better matched.
Changelog
- 2026-05-07: Initial review published based on NeuroMyst Pro published specifications.
What we'll measure on the bench.
- Protocol
- Multimeter at electrodes (current source verification)
- Primary metric
- Output current at each preset (mA)
- Pass threshold
- within ±10% of selected current
- Session shape
- 3 measurements per preset × all presets
§ Bench session pending. Measured values will replace this panel as the protocol completes — see Plate VI · Methodology for the full testing rulebook.